{"entity":{"id":"idea-bio2-tumour-anchored-tgfbeta-trap","kind":"idea","name":"Anchor a TGF-beta trap in the tumour stroma so it cannot act everywhere","aka":[],"tldr":"TGF-beta is a signal that keeps immune cells out of tumours, but blocking it throughout the body caused bleeding and heart toxicity and sank bintrafusp alfa. Tethering the blocker to tumour stroma with a FAP anchor, a collagen-binding domain or a protease-activated mask could give the benefit without the harm.","summary":"Systemic TGF-beta blockade, including the PD-L1-TGF-beta trap bintrafusp alfa, failed largely on a narrow therapeutic index with bleeding and cardiac toxicity. Localisation strategies (a FAP-anchored trap, a collagen-binding domain fusion, or a protease-activated masked format) restrict activity to stroma-rich tumour tissue, and masked antibody formats are already in clinical trials.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)","url":"https://doi.org/10.1001/jamanetworkopen.2019.2535"}],"tags":[],"related":[],"cancers":["urothelial","pancreatic"],"sections":[],"technologies":["masked-adc","bispecific-antibody","checkpoint-inhibitor"],"targets":["fap","pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["desmoplasia","cold-vs-hot"],"trials":[],"people":[],"bottlenecks":["b-tme-immunosuppression","b-toxicity-qol"],"keyPapers":["paper-haslam-jama-netw-open","paper-pd-l1-urothelial-mol-cancer-ther-2015","paper-pd-l1-urothelial-trends-mol-med-2015","paper-pd-l1-urothelial-onco-targets-ther-2016"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A stroma-anchored TGF-beta trap achieves at least tenfold higher tumour-to-plasma target engagement than an unanchored trap and increases T-cell penetration into the tumour core without cardiovascular toxicity.","rationale":"TGF-beta is one of the best-validated barriers to T-cell infiltration in human tumours, notably in urothelial cancer where a stromal TGF-beta signature predicts checkpoint failure. The failure of systemic agents is an index problem, and localisation is the standard fix.","test":"Preclinical head-to-head of anchored versus systemic trap for exposure ratio and toxicity, then a phase 1 with paired biopsies measuring stromal phospho-SMAD2 suppression and CD8 distribution relative to stroma.","maturity":"preclinical-evidence","actor":"industry","cost":"medium","horizonYears":7},"route":"/ideas/idea-bio2-tumour-anchored-tgfbeta-trap/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"masked-adc","kind":"technology","name":"Masked / conditionally active ADC","route":"/technologies/masked-adc/"}],"target":[{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"term":[{"id":"desmoplasia","kind":"term","name":"Desmoplasia (tumour stroma)","route":"/terms/desmoplasia/"},{"id":"cold-vs-hot","kind":"term","name":"Hot vs cold tumours","route":"/terms/cold-vs-hot/"}],"bottleneck":[{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}],"paper":[{"id":"paper-haslam-jama-netw-open","kind":"paper","name":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","route":"/key-papers/paper-haslam-jama-netw-open/"},{"id":"paper-pd-l1-urothelial-trends-mol-med-2015","kind":"paper","name":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","route":"/key-papers/paper-pd-l1-urothelial-trends-mol-med-2015/"},{"id":"paper-pd-l1-urothelial-mol-cancer-ther-2015","kind":"paper","name":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","route":"/key-papers/paper-pd-l1-urothelial-mol-cancer-ther-2015/"},{"id":"paper-pd-l1-urothelial-onco-targets-ther-2016","kind":"paper","name":"PD-L1 expression in human cancers and its association with clinical outcomes","route":"/key-papers/paper-pd-l1-urothelial-onco-targets-ther-2016/"}]}}